Elena V. Deripapa

Elena V. Deripapa

Auto-generated profile, based on publicly available information

Elena V. Deripapa

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BWBeata Wolska-Kusnierz
Beata Wolska-Kusnierz
APAgata Pastorczak
Agata Pastorczak
WFWojciech Fendler
Wojciech Fendler
AWAnna Wakulinska
Anna Wakulinska
BDBozena Dembowska-Baginska
Bozena Dembowska-Baginska
WMWojciech Młynarski
Wojciech Młynarski
Purpose: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. Experimental Design: We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency. Results: Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors n = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7–21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; P < 10−5). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; P = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138–0.162); P < 0.0001]. Conclusions: There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer.

31 October 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AKAnna Khoreva
Anna Khoreva
IAIrina Abramova
Irina Abramova
EDElena Deripapa
Elena Deripapa
YRYulia Rodina
Yulia Rodina
ARAnna Roppelt
Anna Roppelt
ASAnna Shcherbina
Anna Shcherbina
Summary: Wiskott–Aldrich syndrome (WAS) is a life‐threatening primary immunodeficiency associated with bleeding of variable severity due to thrombocytopenia. Correction of the thrombocytopenia is of paramount importance for most WAS patients. We report a retrospective analysis of the safety and efficacy of romiplostim treatment in reducing thrombocytopenia and bleeding tendency in 67 children (median age 1·3 years) with genetically confirmed WAS, followed in eight months (range, 1–12 months). Complete or partial primary responses regarding platelet counts were observed in 22 (33%) and 18 (27%) subjects, respectively. Yet, even in the non‐responder group, the risk of haemorrhagic events decreased significantly, to 21%, after the first month of treatment. The responses tended to be durable and stable over time, with no significant fluctuations in platelets counts. The results of this retrospective study of a large cohort of WAS patients demonstrates that romiplostim can be used to increase platelet counts and reduce the risks of life‐threatening bleeding in WAS patients awaiting haematopoietic stem cell transplantation or forgoing the procedure for various reasons.

30 June 2020 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ALAlexandra Laberko
Alexandra Laberko
ESElvira Sultanova
Elvira Sultanova
EGElena Gutovskaya
Elena Gutovskaya
SRSvetlana Radygina
Svetlana Radygina
EDElena Deripapa
Elena Deripapa
DBDmitry Balashov
Dmitry Balashov

3 May 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ALAlexandra Laberko
Alexandra Laberko
DBDmitry Balashov
Dmitry Balashov
EDElena Deripapa
Elena Deripapa
OSOlga Soldatkina
Olga Soldatkina
ERElena Raikina
Elena Raikina
ASAnna Shcherbina
Anna Shcherbina
Mosaic variegated aneuploidy (MVA) syndrome is a chromosomal instability disorder that leads to aneuploidies of different chromosomes in various tissues. Type 1 MVA (MVA1) is caused by mutations in the budding uninhibited by benzimidazoles 1 homolog beta (BUB1B) gene. The main clinical features of MVA1 syndrome are growth and mental retardation, central nervous system anomalies, microcephaly, and predisposition to cancers. There have been no reports of hematopoietic stem cell transplantation (HSCT) in MVA patients. We report an 11-year old boy diagnosed with MVA1 syndrome. The BUB1B gene mutations c.498_505delAAACTTTA and c.1288 + 5G > A were detected using the next generation sequencing (NGS) method. The patient presented with cytopenia soon after birth, but remained stable until 9 years of age, when he developed myelodysplastic syndrome associated with monosomy of chromosome 7. Due to severe dependence on blood transfusions, a TCRαβ+/CD19+ depleted HSCT was performed from a matched unrelated donor (MUD) using a treosulfan-based reduced intensity conditioning (RIC) regimen. The engraftment occurred, and no severe toxicity was observed soon after the HSCT, but on day + 47, graft rejection was detected. It was followed by prolonged pancytopenia and sepsis with multi-organ Enterococcus faecium infection, which led to the patient’s death on day + 156 after HSCT. In conclusion, we demonstrate that RIC HSCT with TCRαβ+/CD19+ depletion was well tolerated and resulted in complete hematologic recovery in our MVA1 patient, but, unfortunately, it was followed by rapid graft rejection. This fact needs to be taken into consideration for HSCT in other MVA patients.

1 January 2016 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Closed access
ISI.N. Smirnova
I.N. Smirnova
YRYu.A. Rodina
Yu.A. Rodina
EDE.V. Deripapa
E.V. Deripapa
ARA.A. Roppelt
A.A. Roppelt
ALA.L. Laberko
A.L. Laberko
MGMoscow Pediatric Municipal Clinical Hospital No. 9 Named After G.N.Speransky
Moscow Pediatric Municipal Clinical Hospital No. 9 Named After G.N.Speransky

12 May 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AAA. Ya. Avedova
A. Ya. Avedova
YRYulia Rodina
Yulia Rodina
DYD. V. Yukhacheva
D. V. Yukhacheva
VBV. I. Burlakov
V. I. Burlakov
EDE. V. Deripapa
E. V. Deripapa
ASA. Yu. Shcherbina
A. Yu. Shcherbina
Immunoglobulin replacement therapy is the gold standard of treatment for patients with antibody deficiencies. We aimed to investigate the efficacy and safety of replacement therapy with subcutaneous immunoglobulin (SCIG) Hizentra in patients with primary immunodeficiencies. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All patients and / or their legal representatives gave informed consent for this treatment. In our study, 12 patients under 18 years of age with various forms of primary immunodeficiencies who had previously received intravenous immunoglobulin were switched to SCIG treatment to receive weekly infusions of Hizentra. Therapy SCIG was administered weekly at a dose of 0.1–0.15 g/kg by rapid push infusion. All patients received Hizentra for at least 3 months. None of the patients included in the study developed severe infections. Immunoglobulin G levels in blood after 3 months of SCIG therapy were significantly higher compared to those achieved on previous intravenous immunoglobulin therapy. There were no severe adverse events associated with Hizentra administration. Our study demonstrated Hizentra to be effective and safe for the treatment of children with various forms of primary immunodeficiencies.